A tier · strong
Afamelanotide is genuinely FDA- and EMA-approved with two vehicle-controlled randomised trials behind it, but the approval is a narrow orphan indication in erythropoietic protoporphyria delivered by a specific bioresorbable implant, not a general-purpose tanning product.
melanotan i
Afamelanotide is a synthetic alpha-melanocyte-stimulating hormone analogue approved as SCENESSE, a 16 mg bioresorbable subcutaneous implant, to increase pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. The approval rests on two vehicle-controlled trials in that rare disease and says nothing about the safety or efficacy of research vials injected for cosmetic tanning, which is a different product, a different route and a different use.
the explanation
Afamelanotide tells pigment cells to make more of the dark pigment eumelanin, and as SCENESSE it is a genuinely approved medicine - a tiny rod implanted under the skin every two months for people with a rare condition that makes sunlight painful. The vials sold online for tanning are not that product: different manufacturing, different delivery, and no trial has ever tested them.
regulatory status
FDA and EMA approved for a narrow orphan indication as SCENESSE; all other presentations unapproved
FDA approved SCENESSE (afamelanotide 16 mg implant, NDA 210797) on 8 October 2019 as a New Molecular Entity with priority review for an orphan indication: increasing pain-free light exposure in adults with a history of phototoxic reactions from erythropoietic protoporphyria. The EU marketing authorisation dates to 22 December 2014 for prevention of phototoxicity in adult EPP patients, with the orphan designation lapsing in December 2024 at the end of market exclusivity. There is no approval for cosmetic tanning anywhere, and FDA has issued warning letters over unapproved injectable tanning products; vials sold as melanotan are unapproved drugs.
how it works · proposed mechanism
Afamelanotide works by sustained agonism at melanocortin receptors, principally MC1R on epidermal melanocytes.
MC1R agonism and eumelanin
Binding MC1R raises intracellular cAMP and activates MITF, upregulating tyrosinase and shifting pigment synthesis toward photoprotective eumelanin. The result is skin darkening that is independent of ultraviolet exposure.
Protease-resistant redesign
Substituting norleucine at position 4 and D-phenylalanine at position 7 blocks the enzymatic cleavage that limits native alpha-MSH to minutes of activity. This is what makes the molecule usable as a drug at all.
Controlled-release implant
The approved product is a solid bioresorbable rod placed subcutaneously above the anterior supra-iliac crest every two months, giving steady release. This delivery format, not the peptide alone, generated the approved efficacy and safety data.
what’s reported
evidence shape
6 sourcesThe composition of the cited literature by study type. This describes the shape of the evidence, not its quality — and it does not by itself set the grade.
⚠ the catch
The FDA approval that makes this the highest-graded compound in this group belongs to a refrigerated 16 mg bioresorbable implant placed by a certified clinician every two months for a rare metabolic photosensitivity disorder - not to reconstituted powder injected for a tan. Grading the vial on the implant's approval is exactly the substitution that consumer marketing invites and that this index does not endorse.
key published findings
- Human trial (randomised vehicle-controlled, study CUV039, n=93, 48 SCENESSE vs 45 vehicle, 180 days, three implants): median total hours over 180 days spent in direct sunlight between 10 am and 6 pm on pain-free days was 64.1 hours with SCENESSE versus 40.5 hours with vehicle.
- Human trial (randomised vehicle-controlled, study CUV029, n=74, 38 SCENESSE vs 36 vehicle, 270 days, five implants): median total hours over 270 days spent outdoors between 10 am and 3 pm on pain-free days for which most of the day was in direct sunlight was 6.0 hours with SCENESSE versus 0.75 hours with vehicle.
- Human pharmacokinetics (FDA label): apparent half-life approximately 15 hours from the controlled-release implant, with median Tmax about 36 hours; elimination is believed to occur primarily by hydrolysis and is not fully characterised.
- Human safety (FDA label, adverse reactions above 2%): implant site reaction 21%, nausea 19%, oropharyngeal pain 7%, cough 6%, fatigue 6%, skin hyperpigmentation 4%, dizziness 4%, melanocytic nevus 4%, respiratory infection 4%.
- Regulatory: FDA approval 8 October 2019 (NDA 210797); EU marketing authorisation 22 December 2014; both restricted to erythropoietic protoporphyria.
limitations of the evidence
- The approved evidence base is two modest vehicle-controlled trials in a rare disease population totalling 167 participants, with endpoints specific to photosensitivity rather than to pigmentation for cosmetic purposes.
- No trial has evaluated afamelanotide delivered as reconstituted subcutaneous injection from a research vial, which is the form sold as a tanning agent; the pharmacokinetics of the implant do not transfer to bolus injection.
- Long-term melanoma surveillance data in afamelanotide users remain limited, which is precisely why the label mandates twice-yearly full-body skin examination.
documented safety signals
- Serious hypersensitivity reactions including anaphylaxis have been reported and appear in the FDA label warnings.
- The label requires full body skin examination twice yearly to monitor pre-existing and new pigmentary lesions, and notes darkening of pre-existing naevi and ephelides.
- Implant site reactions (21%) and nausea (19%) are the most common adverse reactions on label.
- Melanocortin agonists obtained outside regulated channels have been associated in the dermatology literature with eruptive dysplastic naevi and with case reports of melanoma; most published cases involve melanotan II rather than melanotan I, but the class concern and the absence of skin surveillance in unsupervised use both apply.
- FDA has issued warning letters against sellers of unapproved injectable tanning peptides; unregulated vials have no verified identity, purity or sterility.
identity
| full name | Afamelanotide (Melanotan I) |
| category | Cosmetic |
| modality | peptide |
| formula | C78H111N21O19 (anhydrous free base; supplied as the acetate, C78H111N21O19 . xC2H4O2 where 3 <= x <= 4) |
| molar mass | 1646.85 g/mol |
| cas | 75921-69-6 |
| half-life | Approximately 15 hours apparent half-life when delivered from the 16 mg controlled-release subcutaneous implant, with median time to peak concentration of about 36 hours (FDA label) |
| sequence | Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH2 |
laboratory handling
| storage | The approved implant is stored refrigerated at 2-8C and protected from light. Reference-grade lyophilised peptide is stored frozen, sealed, protected from light and moisture; the two presentations are not interchangeable in any respect. |
| solubility | The acetate salt is water-soluble; the approved product is not a solution at all but a solid poly(lactide-co-glycolide) rod approximately 1.7 cm long and 1.45 mm in diameter designed for slow resorption. |
| co-studied with | The trial evidence covers afamelanotide as monotherapy delivered by implant, on a background of ordinary photoprotective behaviour in EPP patients; no combination has been studied. Melanotan I and melanotan II are different peptides with different receptor selectivity and different safety literatures and should never be treated as interchangeable. |
Handling information describes laboratory practice for a research reagent. It is not a preparation guide for use in humans.
the receipts
6 citedUS Food and Drug Administration label, NDA 210797 · 2024 · official
US Food and Drug Administration · 2019 · official
European Medicines Agency · 2014 · official
Journal of the American Academy of Dermatology · 2013 · review
New England Journal of Medicine · 2015 · randomized
DailyMed, US National Library of Medicine · 2024 · randomized
others in Cosmetic